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Abstract
The epidermal growth factor receptor variant III (EGFRvIII) is associated with increased proliferation of glioma cells.
However, the impact of EGFRvIII on survival of patients with glioblastoma (GBM) has not been definitively estab-
lished. In the present study, we prospectively evaluated 73 patients with primary GBM treated with surgical resec-
tion and standard radio/chemotherapy. The EGFRvIII was assessed by reverse transcription–polymerase chain
reaction (PCR), O6-methylguanine methyltransferase (MGMT) promoter methylation was assessed by methylation-
specific PCR, and phosphatase and tension homolog (PTEN) expression was assessed by immunohistochemistry.
In 14 patients of this series, who presented with tumor recurrence, EGFRvIII was determined by real-time PCR. Sen-
sitivity to temozolomide (TMZ) was assessed in vitro on GBM neurosphere cell cultures with different patterns of
EGFRvIII expression. Age 60 years or younger, preoperative Karnofsky Performance Status score of 70 or higher,
recursive partitioning analysis score III and IV, methylated MGMT, and Ki67 index of 20% or less were significantly
associated with longer overall survival (OS; P= .0069, P= .0035, P= .0007, P= .0437, and P= .0286, respectively).
EGFRvIII identified patients with significantly longer OS (P = .0023) and the association of EGFRvIII/Ki67 of 20% or
less, EGFRvIII/normal PTEN, EGFRvIII/methylated MGMT, and EGFRvIII/normal PTEN/methylated MGMT identified
subgroups of GBM patients with better prognosis. In recurred GBMs, EGFRvIII expression was approximately two-
fold lower than in primary tumors. In vitro, the EGFRvIII-negative GBM neurosphere cells were more resistant to TMZ
than the positive ones. In conclusion, in contrast with previous studies, we found that EGFRvIII is associated with
prolonged survival of GBM patients treated with surgery and radio/chemotherapy. Depletion of EGFRvIII in recurrent
GBMs as well as differential sensitivity to TMZ in vitro indicates that the EGFRvIII-negative cell fraction is involved in
resistance to radio/chemotherapy and tumor repopulation.
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Introduction
Amplification of the epidermal growth factor receptor (EGFR) gene is
the most frequent genetic change associated with glioblastoma (GBM),
which results in overexpression of the transmembrane tyrosine kinase
receptor, EGFR [1]. GBM showing amplified EGFR frequently over-
expresses the receptor variant III (EGFRvIII), which is characterized by
a truncated extracellular domain with ligand-independent constitutive
activity [2–6]. In vitro and in vivo studies have demonstrated that
EGFRvIII confers increased proliferation and invasiveness to glioma
cells [5–8]. However, the role of overexpressed EGFRvIII on the prog-
nosis of GBM patients has not definitively been established [6,9–20].
In this report, we prospectively analyzed the relationship between
EGFRvIII expression and overall survival (OS) in 73 patients with
newly diagnosed GBM treated with gross tumor resection and adju-
vant radiotherapy and temozolomide (TMZ). In patients who under-
went a second surgery for tumor recurrence, we determined the levels
of EGFRvIII both at primary surgery and at recurrence after radio/
chemotherapy, and we correlated them with survival after recurrence.
Finally, we analyzed the sensitivity to TMZ of GBM stem-like cells
with different levels of EGFRvIII expression.
Materials and Methods
Patients
This study includes 73 consecutive adult patients who underwent
craniotomy for resection of histologically confirmed GBM (WHO
grade 4) [21] and who were treated postoperatively with adjuvant
radiotherapy and TMZ at the Università Cattolica del Sacro Cuore,
Rome. All patients provided written informed consent according to
the research proposals approved by the ethical committee of the Uni-
versità Cattolica del Sacro Cuore. Patients of pediatric age and patients
with secondary GBM were not included. The patients were 20 to
80 years old at the time of primary surgery (median age, 61 years;
mean age, 59.9 ± 11.4 years); 45 were men and 28 were women
(Table 1 and Table W1). To evaluate the extent of tumor resection, we
took into consideration both surgeon’s impression at operation and
Gd-enhanced axial T1-weighted magnetic resonance image (MRI) ob-
tained 1 month after surgery, that is before radio/chemotherapy. All
patients received radiotherapy to limited fields (2 Gy per fraction, once
a day, 5 days a week, 60-Gy total dose) and adjuvant TMZ after surgery
[22]. Fourteen patients were operated on again for tumor recurrence by
7 to 58 months after primary surgery; nine were men and five were
women (Table W2). OS was calculated from the date of surgery to death
or end of follow-up.
Immunohistochemical analysis was performed as previously described
[22]. Immunoreactivity for PTEN was performed with mouse mono-
clonal antibody (1:50; clone 28H6; Novo Castra, Newcastle, United
Kingdom). Immunoreactivity was considered as positive when the tumor
cells showed a strong nuclear staining similar to control cells and reduced
when the nuclear staining was absent or reduced compared with normal.
For a semiquantitative immunostaining evaluation, the slides were
screened independently by two pathologists (L.M.L. and M.M.) who
were unaware of the patient prognosis-related information.
Reverse Transcription–Polymerase Chain Reaction
for EGFRvIII
After being deparaffinized, three 10-μm slides were digested over-
night at 55°C in 200 μl of TENS 1× (10 mM Tris pH 7.4, 10 mM
EDTA, 100 mM NaCl, 1% SDS) with 100 mg/ml proteinase K, and
RNA was then extracted by RNAsi mini kit (Qiagen, Milan, Italy),
following the manufacturer’s protocol. To minimize contamination
by normal cells, the tumor areas selected for DNA/RNA extraction
contained at least 80% disease-specific cells. We assessed the quantity
and quality of the RNA spectrophotometrically (E260, E260/E280 ratio,
spectrum 220-320 nm; Biochrom, Cambridge, United Kingdom)
and by separation on an Agilent 2100 Bioanalyzer (Palo Alto, CA).
RNA was treated with RQ1 RNase-Free DNase (Promega, Milan,
Italy), and complementary DNA (cDNA) was synthesized as previ-
ously described using random examers [23]. The quality of the reverse
transcription synthesis was also tested by amplifying cDNA with
primers of housekeeping genes producing fragments with different
lengths. The presence of EGFRvIII was assessed using the same primers
and following the polymerase chain reaction (PCR) conditions de-
scribed by Mellinghoff et al. [13] and by Yoshimoto et al. [24]. These
two methods showed a 100% concordance in our laboratory. β-Actin
amplification was used as an internal control [23]. Specificity of reverse
transcription–PCR product was assessed by direct sequencing, using
the same primers used for PCR amplification (Figure W2).
Real-time PCR for EGFRvIII
Levels of EGFRvIII messenger RNA (mRNA) were assessed by
real-time PCR using SYBR green chemistry. Diluted (1:20) cDNA
(4 μl) was added to a PCR mix containing 8.4 μl of sterile water,
12.5 μl of 2× SYBR mix (Qiagen, Milan, Italy), and 0.05 μl each
of forward and reverse primers (200 mM) to make up a final volume
of 25 μl [23]. Cycling conditions were 95°C for 5 minutes, followed
by 40 cycles of 95°C for 10 seconds and 60°C for 30 seconds, and
80 cycles of 55°C ± 0.5°C per cycle for melting curve analysis in a
iCycler-iQ multicolor real-time PCR detection system (Bio-Rad,
Milan, Italy). Each assay was performed in triplicate, and data were
processed by iCycler-iQ optical system software (Bio-Rad). The
Table 1. Patients’ Characteristic.
Characteristic No. %
n 73 100
Median age at diagnosis (years) 61
Range 20-80
Age classes (years)
18-39 3 4
40-49 8 11
50-59 25 33
60-69 22 31
>70 15 21
Sex
Male 45 61
Female 28 39
KPS
Median (range) 60 (30-90)
≥70 35 47
<70 38 53
Surgery
Total resection 59 79
Partial resection 14 19
RTOG RPA classes
RPA III 4 6
RPA IV 18 24
RPA V 35 49
RPA VI 16 22
RTOG indicates Radiation Therapy Oncology Group.
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average obtained for EGFRvIII was normalized to the average amount
of β-actin for each sample to determine the relative changes in mRNA
expression. A 10-fold serial dilution of 10 ng of plasmid containing the
EGFRvIII demonstrated that the sensibility of this assay was less than
10−2 in our laboratory.
DNA Extraction and Methylation-Specific PCR for
O6-Methylguanine Methyltransferase
Three 10-μm slides were cut from paraffin-embedded tissues, treated
twice with xylene, and then washed with ethanol. DNA was extracted
using the QIAamp tissue kit (Qiagen, Hilden, Germany) according to
the manufacturer’s protocol. Methylation-specific PCR (MS-PCR) for
O6-methylguanine methyltransferase (MGMT) was performed as pre-
viously described [23]. Briefly, bisulfite-modified DNA (100-200 ng) was
amplified in a mixture containing 1× PCR buffer (20 mM Tris pH 8.3,
50 mMKCl, 1.5 mMMgCl2), dNTPs (200 mM each), primers (20 pM
each), and 0.75 U of Taq polymerase platinum (Invitrogen) in a final
volume of 25 μl. PCR conditions were an initial denaturation of 95°C
for 8 minutes, followed by 35 cycles of 95°C for 60 seconds, 60°C
for 60 seconds, and 72°C for 60 seconds. The MS-PCR did not exceed
the 35 amplification cycles. PCR products were electrophoresed in a
2.5% agarose gel, stained with ethidium bromide, and visualized under
UV illumination. In all samples, MS-PCR analyses were performed in
duplicate. Normal lymphocyte DNA supermethylated with SssI
methyltransferase (New England Biolabs, Beverly, MA), treated with
bisulfite, served as the unmethylated and methylated control, water
as a negative control, and untreated DNA as internal PCR control.
As control group, we carried out MS-PCR also on granulocyte DNA
obtained from 10 healthy individuals.
Establishing GBM Neurosphere Cell Cultures
GBM tissue specimens were collected at surgery from adult patients
who had undergone craniotomy at the Institute of Neurosurgery,
Catholic University School of Medicine, Rome. Cell suspension ob-
tained by mechanical dissociation of the tumor tissue was passed
through a 100-μm mesh to remove aggregates and cultivated in a
serum-free medium containing epidermal growth factor and basic
fibroblast growth factor as previously described [22,25]. Cell lines
actively proliferating required 3 to 4 weeks to be established. Isolated
cell lines were expanded and characterized both in vitro and in vivo. In
these conditions, cells were able to grow in vitro in clusters called neuro-
spheres and maintain an undifferentiated state, as indicated by mor-
phology and expression of stem cell markers such as CD133, SOX 2,
Musashi1, and nestin. The in vivo tumorigenic potential of GBM
neurospheres was assayed by intracranial or subcutaneous cell injection
in immunocompromised mice. GBM neurospheres were able to gen-
erate a tumor identical to the human tumor in antigen expression and
histologic tissue organization. Cell lines were used from passage 5 to 10
throughout the study.
In Vitro Sensitivity to TMZ
GBM stem cells were mechanically dissociated and plated at the
density of 2000 cells in 96-well plates in triplicate. After 24 hours of
incubation at 37°C in a 5% CO2, the cells were treated with TMZ
at concentrations of 125, 250, and 500 μM (Schering-Plough,
Kenilworth, NJ). Cells’ viability was evaluated after 24, 48, 72, and
96 hours of treatment by CellTiter Glo luminescent assay according
to the manufacturer’s protocol (Promega).
Semiquantitative RT-PCR Analysis of Bcl-XL Expression
After RNA extraction with RNAsi mini kit (Qiagen, Hilden, Ger-
many), first-strand cDNA was synthesized by 1 μg of RNA using Go-
Script Reverse Transcription System kit according to the manufacturer’s
protocol (Promega). Three microliters of cDNA was amplified with
specific primers for Bcl-XL (5′-TCCTTGTCTACGCTTTCCACG-3′
and 5′-GGTCGCATTGTGGCCTTT-3) and β-actin (5′-TACATG-
GGTGGGGTGTTGAA-3′ 5′-AAGAGAGGCATCCTCACCCT-5′)
in 25 μl of final volume, containing 1 U of GoTaq (Promega), 1 mM
of each primer, 200 mM of dNTPs, and 1× reaction buffer (10 mM
Tris-HCl pH 8.3, 50 mM KCl, 1.5 mMMgCl2). The PCR conditions
were as follows: one cycle of 3 minutes at 95°C, followed by 33 cycles at
95°C for 40 seconds, 58°C for 40 seconds, 72°C for 40 seconds. Themix-
ture was separated on a 2% agarose gel, and after staining with ethidium
bromide, the PCR product was visualized under ultraviolet light. The
Bcl-XL expression were subjected to densitometric analysis by using the
Gel-Doc 2000 Quantity One program (Bio-Rad), after normalization
with the β-actin intensity.
Statistical Analysis
Statistical analysis was performed using STATA 10 (StataCorp LP,
College Station, TX), GraphPad-Prism 5 software (Graph Pad Soft-
ware, San Diego, CA), and MedCalc version 10.2.0.0 (MedCalc
Software, Mariakerke, Belgium). Kaplan-Meier survival curves were
plotted, and differences in survival between groups of patients were
compared using the log-rank test. Statistical comparison of continuous
variables was performed by the Mann-Whitney U test, as appropriate.
Comparison of categorical variables was performed by χ2 statistic, using
the Fisher exact test. Multivariate analysis was performed using the
Cox proportional hazards model, which was adjusted for the major
prognostic factors that included age (≤60 vs >60 years), Karnofsky
Performance Status (KPS; <70 vs≥70), extent of surgical resection (total
vs partial resection),MGMTmethylation status andKi67 index (≤20%
vs >20%). Correlation between EGFRvIII mRNA in recurrent tumors
and survival after recurrence was studied using regression analysis and
the Spearman correlation coefficient. P < .05 were considered as statis-
tically significant.
Results
Clinical and Molecular Parameters
Among the clinical estimates, age 60 years or younger, preopera-
tive KPS score of 70 or higher, and recursive partitioning analysis
(RPA) score III and IV were significantly correlated with longer
OS (P = .0069, HR = 0.43, 95% confidence interval [CI] = 0.23-
0.79 for age; P = .0035, HR = 2.34, 95% CI = 1.32-4.14 for KPS;
P = .0007, HR = 0.35, 95% CI = 0.19-0.64 for RPA; Table 2 and
Figure W1). Patients with totally resected tumors trended to survive
longer than those who had undergone partial tumor resection, although
this difference was not significant. Among the biologic features, GBMs
with EGFRvIII, with MGMT hypermethylation, and with Ki67 index
of 20% or less were associated to a significant longer OS (P = .0023,
HR = 2.59, 95% CI = 1.40-4.79; P = .0437, HR = 1.86, 95% CI =
1.02-3.41; P = .0286, HR = 0.53, 95% CI = 0.30-0.93; Figure 1).
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There was no difference in Ki67 index between EGFRvIII-positive
GBMs and those tumors without EGFRvIII (26.6 ± 13.6 and 25.6 ±
12.3, respectively; 26.0 ± 12.8; P = .75). However, GBMs showing
EGFRvIII and Ki67 index of 20% or less had significantly longer OS
than those with EGFRvIII andKi67 index greater than 20% (P = .0275,
HR = 0.37, 95%CI = 0.15-0.89; Figure 2A). A favorable impact onOS
was also demonstrated for the association between the presence of
EGFRvIII and MGMT promoter methylation (P = .0108, HR =
3.70, 95% CI = 1.35-10.12; Figure 2B), for the association between
the presence of EGFRvIII and normally expressed PTEN (P = .0223,
HR = 0.33, 95% CI = 0.13-0.85; Figure 2C), and for the association
between the presence of EGFRvIII, normally expressed PTEN, and
methylated MGMT (P = .0040, HR = 2.69, 95% CI = 1.37-5.30;
Figure 2D).
A multivariate survival model for OS (Cox proportional hazards
regression analysis) was established that included age, KPS, extent
of resection, Ki67 index, EGFRvIII expression, MGMT promoter
methylation, and PTEN expression (Table W3). Age older than
60 years (P = .0182), KPS score of 70 or higher (P = .0055), Ki67
index of 20% or less (P = .0032), and EGFRvIII (P = .0128)
emerged as independent prognostic factors for OS.
EGFRvIII Expression in Recurrent GBM
Fourteen patients of this series underwent a second operation for
resection of tumors that recurred after radio/chemotherapy (TableW2).
The interval for tumor recurrence ranged from 7 to 58 months. Gross
total resection was achieved in all cases. Histologic sections both of the
primary tumor and of the recurrent one were carefully reviewed and
adjacent slices were dissected to eliminate areas of necrosis and hemor-
rhages. Real-time PCR of such selected regions showed that, relative to
GBMs at primary surgery, the level of EGFRvIII in the recurrent tumors
decreased by approximately 50%on average (range = 40.4%-77.6%). In
four cases, EGFRvIII expression was not detected both in the primary
tumor and in the recurrent one (Table W2). In remaining cases, the
EGFRvIII levels were reduced in seven cases and unchanged in three
cases. Overall, therewas a significant depletion of EGFRvIII in recurrent
GBMs (P = .01, Wilcoxon signed rank test; Figure 3A). Plotting the
EGFRvIII mRNA levels in recurrent tumors against survival after recur-
rence revealed a linear relationship between the two variables (P = .034,
r2 = 0.706, Spearman correlation coefficient; Figure 3B). The same type
of relationship was demonstrated when the EGFRvIII values were
expressed as the ratio between EGFRvIII mRNA after radio/chemo-
therapy and EGFRvIII mRNA before radio/chemotherapy, a method
that attenuates interindividual variability (P = .029, r2 = 0.724, Spearman
correlation coefficient).
Sensitivity to TMZ of GBM Neurosphere Cell Cultures
To investigate the relationship between the presence of EGFRvIII
and sensitivity to TMZ, we used paired GBM neurosphere cell cul-
tures expressing or not the EGFRvIII and which were obtained from
different regions of the same tumor under stem cell culture conditions.
These cells provide a unique model that eliminates the confounding
variables inherent to cells derived from different patients. We and
Table 2. OS for Clinical and Biologic Parameters.
Parameter n Median OS (Months) P
All patients 73 9
Age (years)
≤60 36 18 .0069
>60 37 9
KPS
≥70 35 15 .0035
<70 38 9
Surgery
Total 59 11 .3822
Partial 14 19
RTOG RPA score
III-IV 22 29 .0007
V 35 11
VI 16 8
EGFRvIII
+ 32 19 .0023
− 41 10.5
MGMT
M 32 14 .0437
UM 41 11
PTEN
+ 43 11 .4175
− 30 11
Ki67
≤20% 32 14 .0286
>20% 41 9
M indicates methylated; UM, unmethylated.
Figure 1. Kaplan-Meier survival curves of 73 GBM patients stratified by EGFRvIII, MGMT, and Ki67. The presence of EGFRvIII in tumors
(A, blue line),methylatedMGMT (B, blue line), and Ki67 index of 20%or less (C, blue line), conferred a favorable survival advantage (P= .0023,
P = .0437, and P = .0286, respectively).
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others have demonstrated that such cells, generally referred to as GBM
stem-like cells, retain many biologic and molecular features of the pa-
rental tumor, including resistance to chemotherapeutic agents [26,27].
For this experiment, we used six GBM neurosphere cell cultures that
were obtained from three patients and that showed various combina-
tions of EGFRvIII, PTEN expression, and MGMT promoter methyl-
ation status (Table W4). All of the GBM neurosphere cell lines had
previously been demonstrated to self-renew in vitro and to give rise
to tumor xenografts that recapitulate the phenotype and the histologic
pattern of the parent tumor on orthotopic transplantation in immuno-
compromised mice [22,25].
We found that concentrations of TMZ less than 125 μM had no
significant effect on the growth of GBM cell lines. At higher concen-
trations, however, the EGFRvIII-positive GBM cells were less resistant
to TMZ compared to their EGFRvIII-negative counterparts (Figure 4).
Sensitivity to TMZ correlated with reduction of Bcl-XL mRNA (Fig-
ure 4B)—an antiapoptotic member of BCL-2 family that has been
demonstrated to increase in EGFRvIII-expressing GBM cells and to
be associated with increased chemoresistance [28,29].
Discussion
In this study, we reevaluated the relationship between EGFRvIII in
GBM tumors and survival of patients undergoing gross tumor re-
section and adjuvant radiotherapy and TMZ. To analyze EGFRvIII
presence, we used an RT-PCR assay on selected regions of formalin-
fixed paraffin-embedded tumor specimens. This method, which has
been proven to be more sensitive than immunohistochemistry, detects
EGFRvIII in approximately 27% to 54% of GBMs [12,13,19,24].
Compared with previous studies on the role of EGFRvIII in GBM
Figure 2. Kaplan-Meier survival curves of 73 GBM patients stratified by EGFRvIII/Ki67, EGFRvIII/PTEN, EGFRvIII/MGMT methylation, and
MGMT methylation/PTEN/EGFRvIII. (A) Patients stratified by EGFRvIII/Ki67. EGFRvIII-positive GBMs and Ki67 index of 20% or less (blue
line) was related with longer OS (P = .0275). There were no differences in survival times between the following three unfavorable
groups: EGFRvIII+/Ki67 greater than 20% (gray line), EGFRvIII−/Ki67 20% or less (yellow line), and EGFRvIII−/Ki67 greater than 20%
(red line). (B) Patients stratified by EGFRvIII/MGMT methylation. EGFRvIII-positive GBMs, and methylated MGMT (blue line) was related
with longer OS (P = .0108). There were no differences in survival times between the following three unfavorable groups: EGFRvIII+/
unmethylated MGMT (gray line), EGFRvIII−/methylated MGMT (yellow line), and EGFRvIII−/unmethylated MGMT (red line). (C) Patients
stratified by EGFRvIII/PTEN. The presence of EGFRvIII and normal expression of PTEN (blue line) was associated with longer OS (P =
.0223). There were no differences in survival times between the following three unfavorable groups: EGFRvIII+/hypoexpression of PTEN
(−) (gray line), EGFRvIII−/PTEN− (yellow line), and EGFRvIII−/PTEN+ (red line). (D) Patients stratified by MGMT methylation/PTEN/
EGFRvIII. The association of methylated MGMT, normal expression of PTEN, and presence of EGFRvIII (blue line) was associated with
longer OS (P = .004).
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tumor biology, we used two additional approaches. The first one
consisted in measuring the level of EGFRvIII mRNA both in GBMs
at primary surgery and in those that recurred after radio/chemotherapy.
Enrichment or depletion of EGFRvIII mRNA in the recurrent tumors
would informwhether the EGFRvIII statusmight play any role in radio/
chemoresistance and repopulation potential. The second approach used
GBM neurosphere cell cultures expressing or not the EGFRvIII to test
in vitro sensitivity to TMZ. We and others have recently established
multiple stem-like cell lines with distinct expression profiles from differ-
ent areas of the same GBM tumor [25,30]. These cells probably share
a common ancestor but divergent genomic evolution and molecular
properties [30,31].
Major results were as follows: 1) the presence of EGFRvIII in GBM
tumors correlates with longer OS. The association of EGFRvIII/Ki67
of 20% or less, of EGFRvIII/normal PTEN, and of EGFRvIII/
methylated MGMT identified subgroups of GBM patients with better
prognosis; 2) EGFRvIII expression is reduced in GBM recurring after
adjuvant radiotherapy and TMZ; and 3) EGFRvIII-positive GBM
neurosphere cells are less resistant to TMZ than their EGFRvIII-
negative counterparts.
Our findings on the prognostic significance of EGFRvIII in GBM
diverge from previous studies, where this variant was found either to
be unrelated to the patients’ outcome [6,11,12,16–20] or to be associ-
ated with shorter survival (Table W5) [10,14]. Although in the study
by Brown et al. [16] the presence of EGFRvIII was not significantly
predictive, patients with high-level (greater than a doubling in EGFR
copy number) versus low-level EGFR gene amplification showed a trend
to better OS. It is worth noticing that the mechanisms linking EGFR-
vIII and clinical outcome have not generally been addressed. The few
observations that have been made in this regard yielded apparently dis-
crepant results, like that EGFRvIII does not relate with cell prolifera-
tion and aggressive tumor features, as expected from in vitro data [11],
and that the downstream effectors of Ras are prognostic only in the
EGFRvIII-negative patients [14]. In contrast, we found that in the
EGFRvIII-positive GBMs, a Ki67 index of 20% or less identified pa-
tients with better prognosis. Reportedly, GBMs with high proliferative
index are clinically more aggressive and are characterized by deregula-
tion of many different molecular pathways [32–34]. Proliferation rate,
however, did not account for the worse prognosis of EGFRvIII-
negativeGBMs, suggesting differentmechanisms of tumor aggressiveness
in these neoplasms. The favorable effect of EGFRvIII on prognosis was
abrogated either in the absence of the tumor-suppressor protein PTEN
or in cases with unmethylated MGMT, which is consistent with the
notion that PTEN has a key role in the inhibition of the antiapoptotic
signals of the activated PI3K-Akt pathway and that epigenetic silencing
of MGMT through promoter methylation is related with improved
outcome and response to TMZ in malignant gliomas [13,35,36].
The better survival of patients showing EGFRvIII and PTEN expres-
sion seems somewhat contradictory, given that activation of PI3K-
Akt pathway is one of the most important transduction signaling of
EGFRvIII and that PTEN represents a major inhibitor of PI3K-Akt
pathway. We may speculate that loss of PTEN reduced OS in our
patients through a PI3K-mediated radioresistance [37,38], whereas
the EGFRvIII-positive stem-like fraction of the tumor cells was more
sensitive to TMZ therapy.
To resolve the difference in the prognostic value of EGFRvIII be-
tween the current study and the previous ones, it may be postulated
that very low levels of EGFRvIII would have been detected by RT-
PCR as opposed to immunohistochemistry where these specimens
would likely have been determined as negative. There may be a
threshold of expression necessary that allows for dimerization with
possibly differential signaling that results in the negative/neutral
prognostic influence of EGFRvIII found in previously published
studies. Although EGFRvIII receptor dimerization was not consid-
ered initially as factor in the signaling activity [39], this premise is
being revisited by investigators who have shown that chemical in-
ducers of EGFRvIII dimerization produce a more oncogenic form
of the EGFRvIII [40]. However, the concept of an EGFRvIII expres-
sion threshold for dimerization does not seem to be confirmed by our
real-time PCR analysis on recurrent tumors, which shows a linear
relationship between EGFRvIII levels and survival.
A unique aspect of the present study that may help explaining the
discrepancy between our results and previous clinical data is that our
patient population is a uniform surgical, radiotherapy, and TMZ co-
hort. Previous studies included patients treated with surgery and frac-
tionated radiotherapy, where chemotherapy regimens were vastly
different. Although some of these studies did contain a substantial
number of patients treated with TMZ, the findings about EGFRvIII
and prognosis were not placed in the context of TMZ treatment
[14,16,17]. For example, in the study by Pelloski et al. [14], patients
were not stratified for TMZ treatment. In the studies by Brown et al.
[16] and by Van den Bent et al. [17], TMZ-treated patients either
concurrently received the EGFR inhibitor erlotinib or were incorpo-
rated into the control arm, which included patients treated with car-
mustine, so that EGFRvIII expression and response to TMZ could
not be related to each other.
Figure 3. Expression of EGFRvIII in recurrent GBM. (A) Box-and-
whisker plots showing significant reduction of EGFRvIII mRNA levels
in recurrent GBM in comparison to the primary tumors (Wilcoxon
signed rank test). (B)Graph showing the relationship between survival
after tumor recurrence and level of EGFRvIII mRNA expression in the
recurrent tumor (Spearman correlation coefficient).
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Our data suggest that sensitivity to TMZ may be related with
EGFR expression and that in the tumor context the cell fraction with
constitutively activated EGFR may be less resistant to TMZ. In mice
grafted with EGFRvIII-positive human GBM cells, TMZ either alone
or in combination with inhibitors of the EGFR tyrosine kinase induced
significant reduction of the tumor xenografts [41]. Meta-analysis
showed that among GBM patients treated with TMZ, EGFRvIII-
positive GBMs showed significantly longer survival relative to the
EGFRvIII-negative ones (P < .05) [13]. The hypothesis that the
EGFRvIII status may affect sensitivity to TMZ of GBM cells has been
confirmed by our in vitro experiments, where the absence of EGFRvIII
conferred a higher resistance to TMZ. It should be emphasized that
these results were obtained using GBM cultures enriched with so-called
cancer stem cells, having or not EGFRvIII, and that this model is much
closer to the clinical condition than those models based on serum-
exposed virus-transfectedGBMcell lines [6–8,13]. The higher sensitivity
of EGFRvIII-positive GBM cells to TMZ may be ascribed to a mecha-
nism of intrinsic nononcogene addiction [42]. In the EGFRvIII-positive
tumor cells, which are chronically dependent on persistent signaling, the
rate of spontaneous DNA damage and the degree of replication stress are
enhanced. It is likely that in this condition of stress overload, the cancer
cells with already elevated levels of DNA damage and replication stress
cannot repair the additional damage induced by TMZ.
In the present study, we found a not significant trend to longer
survival for patients whose tumors had been totally resected compared
with those patients who had undergone partial tumor resection. The
role of extent of surgical resection in determining the prognosis of
GBM patients is still a matter of debate. Although most authors state
that maximal safe resection is associated with better survival, it has been
noted that no class I evidence exists [43]. The relatively small number
of patients in our series as well as the method we used to evaluate the
extent of tumor resection, which was based on surgeon’s impression
and Gd-enhanced MRI obtained 1 month after surgery and not within
72 hours, may be influential in explaining our result.
Overall, our findings are consistent with a cancer stem cell model
for GBM where the mutation of EGFR occurs at the stage of early
progenitor cells concurrent with the increase of proliferation from
early to late progenitors, where the latter cells are thought to be
Figure 4. Cell viability percentages of GBM neurosphere cells with different patterns of EGFRvIII expression, MGMT methylation status,
and PTEN expression (Table W4) treated for 24, 48, 72, and 96 hours with TMZ at 125, 250, and 500 μM. Each experiment was repeated
three times, and mean values were plotted. (A) Cell survival curves comparing sensitivity to TMZ of cell line 1A (blue; EGFRvIII−/MGMT
unmethylated/PTEN+) versus cell line 1B (orange; EGFRvIII+/MGMT unmethylated/PTEN+). (B) Semiquantitative RT-PCR analysis of
Bcl-XL mRNA expression by the EGFRvIII-positive cell line 1B and by EGFRvIII-negative cell line 1A at 0, 48, and 72 hours exposure
to 500 μM TMZ in culture. Upper panel, representative experiment (MW, molecular weight; −, negative control). Lower panel, semi-
quantitative analysis of Bcl-xL mRNA expression from three different experiments in EGFR-positive (orange) and in EGFR-negative (blue)
neurosphere cell line. (C) Cell survival curves comparing sensitivity to TMZ of cell line 2A (orange; EGFRvIII+/MGMT methylated/PTEN+)
versus cell line 2B (blue; EGFRvIII−/MGMT methylated/PTEN+). (D) Cell survival curves comparing sensitivity to TMZ of cell line 3A (light
blue; EGFRvIII−/MGMT methylated/PTEN−) versus cell line 3B (dark blue; EGFRvIII−/MGMT unmethylated/PTEN−).
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responsible for tumor bulk but not for tumor recurrence. Mechanis-
tically, a ligand-independent constitutively activated EGFR is hardly
plausible in cancer stem cells, which are highly dependent on the
exogenous supply of EGF for their in vitro growth.
In summary, this study shows that EGFRvIII is a molecular pre-
dictor of longer OS in GBM patients treated with surgery followed
by adjuvant radiotherapy and TMZ. This effect may be ascribed to a
better response to TMZ and to a lower repopulation potential by the
EGFRvIII-positive GBM cells.
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Table W1. Summary of Clinical and Molecular Data of 73 Primary GBMs at First Surgery.
Patient No. Age (Years)/Sex KPS RPA Class Surgical Resection Ki67 (%) EGFRvIII MGMT PTEN Overall Survival (Months)
1 54/F 80 IV P 40 + M + 35
2 72/F 40 VI T 40 − M + 3.5
3 42/F 90 III T 15 + M + 75
4 69/M 80 IV T 40 + M + 12.5
5 56/M 50 VI T 15 − UM − 2
6 47/M 70 IV P 35 − M − 12.5
7 56/M 90 IV T 20 + UM + 12
8 66/M 90 IV T 40 − UM − 12
9 51/F 50 V T 50 − UM + 11
10 75/F 50 V P 20 + UM − 5.5
11 61/M 60 VI T 40 − UM − 9
12 56/M 60 V T 25 + M − 23
13 61/M 50 VI T 30 − UM + 2
14 59/F 60 V T 50 + UM + 10
15 77/F 50 V T 20 + UM + 6.5
16 30/F 90 III T 50 + M + 55
17 77/M 90 V T 60 + UM − 9
18 69/M 70 V T 50 − M + 4
19 72/F 80 V T 5 + UM − 7.5
20 76/M 90 V P 8 − UM + 7.5
21 62/F 80 V T 20 + UM + 6
22 47/M 90 III T 30 − M − 7
23 49/M 70 IV P 15 + M + 36
24 64/F 50 VI P 35 − M + 6
25 53/F 70 V T 25 − UM + 15
26 67/F 50 V T 20 − UM − 5
27 58/F 80 V P 25 + UM + 2
28 51/F 50 V T 20 − UM − 21
29 68/M 80 V T 15 + UM + 24
30 64/F 60 VI T 10 + M + 19
31 55/M 80 V P 30 + M + 7
32 46/M 60 IV P 10 − M − 6.5
33 72/M 40 V T 20 − UM + 11
34 54/F 60 V T 5 + UM + 18
35 48/F 70 IV T 15 − M + 6
36 58/M 60 V T 10 − UM + 10.5
37 51/M 90 IV P 25 − UM + 12.5
38 73/M 50 VI T 25 − UM − 2
39 66/M 90 V P 10 − UM − 11
40 59/M 80 V T 35 + UM + 6
41 64/M 80 V T 10 − M + 14
42 74/M 60 VI T 15 − M − 5.5
43 50/M 90 IV T 30 − M − 11
44 62/F 60 VI T 35 + M − 19
45 20/M 90 III T 20 + M − 27.5
46 70/F 60 V T 15 + UM + 8
47 70/M 50 VI T 20 − M + 9
48 66/M 30 VI T 25 − M + 3.5
49 52/F 60 V T 20 + M − 26
50 64/M 90 IV T 15 − M − 15
51 53/M 80 V T 30 + UM + 11
52 61/M 90 IV T 15 − M − 22
53 58/M 70 V T 35 + UM − 12.5
54 56/F 90 IV T 25 + UM − 12
55 52/M 60 VI T 50 + UM + 10
56 67/M 70 V T 30 − M − 7.5
57 75/F 30 VI T 50 − UM − 2
58 48/M 80 IV T 50 + M − 4
59 67/F 60 V T 20 + UM − 20
60 71/F 60 V P 20 − M + 3
61 76/F 60 V P 25 + M − 4
62 52/M 90 IV T 30 − UM + 20
63 69/F 40 VI T 25 + UM − 3
64 48/M 30 IV T 25 − UM − 2
65 69/F 60 VI T 25 − UM + 11
66 52/M 60 V P 20 − UM + 19
67 58/M 40 VI T 30 − UM + 8
68 55/M 50 V T 50 − UM + 2
69 68/M 50 VI T 25 + UM − 8
70 80/M 70 V T 25 + M + 4.5
71 33/M 50 IV T 20 + M + 65
72 67/F 60 V T 10 − UM + 10
73 59/M 70 IV T 10 + M + 18
Table W2. Summary of Clinical and Molecular Data of 14 Recurrent GBMs.
Patient No. KPS RPA Class Time for Recurrence (Months) Ki67 (%) EGFRvIII MGMT PTEN Survival after Recurrence (Months)
1 70 V 28 40 + M + 7
12 60 V 18 20 + M − 5
16 80 IV 48 50 + UM + 7
23 70 IV 26 12 + UM + 10
28 50 V 17 25 − M − 4
30 60 VI 13 10 + M + 6
43 80 V 9 30 − M − 2
50 90 IV 8 25 − M − 7
51 80 V 7 40 + UM + 4
52 80 V 13 20 − M − 9
55 60 VI 8.5 40 + UM + 1.5
59 60 V 17 20 + UM − 3
71 50 IV 58 30 + M + 7
73 60 V 12 25 + M + 6
Figure W1. Kaplan-Meier survival curves of 73 GBM patients stratified by age, KPS, and RPA class. (A) Age 60 years or younger (blue line)
conferred a favorable survival advantage (P= .0069). (B) KPS score of 70 or higher (blue line) was related with longer OS (P= .0035). (C) RPA
classes III-IV (blue and gray lines) were associated with longer OS (P= .0007). There were no differences in survival times between the RPA
class V (yellow line) and VI (red line).
Table W3. Multivariate Analysis for OS.
Covariate b SE P Exp(b) 95% CI of Exp(b)
EGFRvIII −0.8330 0.3346 .0128 0.4347 0.2264-0.8349
Age 0.7596 0.3218 .0182 2.1374 1.1412-4.0033
KPS −0.8524 0.3069 .0055 0.4264 0.2344-0.7757
Ki67 0.8817 0.2993 .0032 2.4150 1.3472-4.3292
MGMT status −0.3326 0.3334 .3186 0.7171 0.3743-1.3739
PTEN expression 0.1591 0.3018 .5979 1.1725 0.6509-2.1120
Resection 0.0679 0.4316 .8749 1.0703 0.4613-2.4832
In bold the statistically significant P (P < .05).
Table W4. Molecular Profile of Parent GBM and Neurosphere Cell Cultures.
No.
Parent GBM Tissue
GBM Neurosphere Cultures
Culture A Culture B
EGFRvIII MGMT PTEN EGFRvIII MGMT PTEN EGFRvIII MGMT PTEN
1 Positive M Normal Negative UM Normal Positive UM Normal
2 Positive M Normal Positive M Normal Negative M Normal
3 Negative UM Low Negative M Low Negative UM Low
Figure W2. RT-PCR assessment for EGFRvIII on selected regions of formalin-fixed paraffin-embedded tumor specimens. (A) EGFRvIII
RT-PCR performed on eight GBMs representative cases. The EGFRvIII is present only in samples 1, 4, and 5. Water was used as neg-
ative control (−) and plasmid containing EGFRvIII as positive control (+). MW indicates molecular weight marker. (B) Partial sequence of
EGFR cDNA showing the deletion of EGFRvIII.
Table W5. Summary of Studies on EGFRvIII Expression and Prognosis of GBM Patients.
Author, Year No. Cases Technique Results Proposed Mechanism
Feldkamp et al., 1999* 12 IHC, RT-PCR, Western blot analysis Worse prognosis (ns) None
Shinojima et al., 2003† 87 IHC Worse prognosis (s) EFGR amplification
Aldape et al., 2004‡ 105 IHC, RT-PCR No prognostic value, worse prognosis in AAs EGFRvIII as marker of GBM-like cells in AAs
Heimberger et al., 2005§ 196 IHC Worse prognosis for patients surviving >1 year Cell proliferation (ns), ependymal involvement (ns)
Liu et al., 2005¶ 160 RT-PCR No prognostic value Older age in AAs
Heimberger et al., 2005♯ 54 IHC No prognostic value None
Mellinghoff et al., 2005** 50 IHC, RT-PCR, Western blot analysis Better prognosis in the erlotinib arm PTEN coexpression
Pelloski et al., 2007†† 509 IHC Worse prognosis (s) None
Viana-Pereira et al., 2008‡‡ 27 IHC No prognostic value None
Brown et al., 2008§§ 81 IHC No prognostic value None
van den Bent et al., 2009¶¶ 49 IHC No prognostic value, worse prognosis in the erlotinib arm None
Thiessen et al., 2010♯♯ 16 Real-time PCR No prognostic value None
Reardon et al., 2010*** 20 IHC No prognostic value None
AA indicates anaplastic astrocytoma; IHC, immunohistochemistry; ns, not significant; s, significant.
*Feldkamp MM, Lala P, Lau N, Roncari L, and Guha A (1999). Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human
glioblastoma multiforme specimens. Neurosurgery 45, 1442–1453.
†Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, et al. (2003). Prognostic value of epidermal growth factor receptor in patients with
glioblastoma multiforme. Cancer Res 63, 6962–6970.
‡Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, and James CD (2004). Immunohistochemical detection of EGFRvIII in high malignancy grade
astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63, 700–707.
§Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, and Aldape K (2005). Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme
patients. Clin Cancer Res 11, 1462–1466.
¶Liu L, Bäcklund LM, Nilsson BR, Grandér D, Ichimura K, Goike HM, and Collins VP (2005). Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally
treated astrocytic gliomas. J Mol Med (Berl) 83, 917–926.
#Heimberger AB, Suki D, Yang D, Shi W, and Aldape K (2005). The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 3, 38.
**Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, et al. (2005). Molecular determinants of the response of glioblastomas to EGFR
kinase inhibitors. N Engl J Med 353, 2012–2024.
††Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, et al. (2007). Epidermal growth factor receptor variant III status defines clinically
distinct subtypes of glioblastoma. J Clin Oncol 25, 2288–2294.
‡‡Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F, Jones C, and Reis RM (2008). Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in
Portuguese high-grade gliomas. Anticancer Res 28, 913–920.
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